文献速递冠心病血脂与心血管预防

依洛尤单抗对心血管疾病患者总心血管事件的影响:FOURIER 试验预设分析

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
PubMed 文献 · JAMA Cardiol · 2019-01-01

IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first cardiovascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, but patients remain at high risk of recurre…

要点

  • 依洛尤单抗减少总主要终点事件 18%,包括首次事件和后续事件。
  • 总事件减少由心肌梗死、卒中和冠脉血运重建的减少驱动。
  • 每 1000 例治疗 3 年预防 22 次首次事件和 52 次总事件。

核心结论

  • 在他汀治疗基础上加用依洛尤单抗可显著减少总主要终点事件,且预防的总事件数超过仅分析首次事件时的两倍。

主要发现

  • 依洛尤单抗组总主要终点事件 2192 次,安慰剂组 2714 次。
  • 每 1000 例患者治疗 3 年,依洛尤单抗预防 22 次首次主要终点事件和 52 次总主要终点事件。

临床怎么用

  • 对于接受他汀治疗的稳定性动脉粥样硬化患者,加用依洛尤单抗可进一步减少总心血管事件负担。
  • 评估降脂治疗获益时应关注总事件而不仅是首次事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first cardiovascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, but patients remain at high risk of recurrent cardiovascular events. OBJECTIVE: To evaluate the effect of evolocumab on total cardiovascular events, given the importance of total number of cardiovascular events to patients, clinicians, and health economists. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of a randomized, double-blind clinical trial. The FOURIER trial compared evolocumab or matching placebo and followed up patients for a median of 2.2 years. The study included 27 564 patients with stable atherosclerotic disease receiving statin therapy. Data were analyzed between May 2017 and February 2019. MAIN OUTCOMES AND MEASURES: The primary end point (PEP) was time to first cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; the key secondary end point was time to first cardiovascular death, myocardial infarction, or stroke. In a prespecified analysis, total cardiovascular events were evaluated between treatment arms. RESULTS: The mean age of patients was 63 years, 69% of patients were taking high-intensity statin therapy, and the median LDL-C at baseline was 92 mg/dL (to convert to millimoles per liter, multiply by 0.0259). There were 2907 first PEP events and 4906 total PEP events during the trial. Evolocumab reduced total PEP events by 18% (incidence rate ratio [RR], 0.82; 95% CI, 0.75-0.90; P < .001) including both first events (hazard ratio, 0.85; 95% CI, 0.79-0.92; P < .001) and subsequent events (RR, 0.74; 95% CI, 0.65-0.85). There were 2192 total primary events in the evolocumab group and 2714 total events in the placebo group. For every 1000 patients treated for 3 years, evolocumab prevented 22 first PEP events and 52 total PEP events. Reductions in total events were driven by fewer total myocardial infarctions (RR, 0.74; 95% CI, 0.65-0.84; P < .001), strokes (RR, 0.77; 95% CI, 0.64-0.93; P = .007), and coronary revascularizations (RR, 0.78; 95% CI, 0.71-0.87; P < .001). CONCLUSIONS AND RELEVANCE: The addition of the PCSK9 inhibitor evolocumab to statin therapy improved clinical outcomes, with significant reductions in total PEP events, driven by decreases in myocardial infarction, stroke, and coronary revascularization. More than double the number of events were prevented with evolocumab vs placebo as compared with the analysis of only first events. These data provide further support for the benefit of continuing aggressive lipid-lowering therapy to prevent recurrent cardiovascular events. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01764633.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019. PMID: 31116355. doi:10.1001/jamacardio.2019.0886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。